SNDX Q3 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+3165.2% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$20M-161.9% margin

Net Income

-$21M-166.8% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+3165.2%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$240M

Total Liabilities

$40M

Stockholders' Equity

$199M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$379,000	+3165.2%
Gross Profit	$12M	$379,000	+3165.2%
Operating Income	-$20M	-$20M	-0.9%
Net Income	-$21M	-$20M	-1.0%